Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
NCT ID: NCT00838240
Last Updated: 2012-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
114 participants
INTERVENTIONAL
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works when given together with cytarabine and idarubicin in treating patients with intermediate-risk or high-risk acute myeloid leukemia or high-risk myelodysplasia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To determine the optimum dose of clofarabine in combination with cytarabine and idarubicin in patients with previously untreated intermediate- and high-risk acute myeloid leukemia or high-risk myelodysplasia. (Phase I)
* To determine the safety and tolerance of this regimen in order to determine the recommended phase II dose. (Phase I)
* To explore the antitumor activity of this regimen in these patients. (Phase II)
* To determine the activity expressed as complete remission (CR)/CR with incomplete hematopoietic recovery (CRi) rate following induction therapy. (Phase II)
Secondary
* To determine the activity expressed as CR/CRi rate following induction (1 or 2 courses) and consolidation therapy. (Phase I)
* To determine hematopoietic recovery (platelets and neutrophils) after induction and consolidation therapy.
* To determine safety and tolerability of this regimen. (Phase II)
* To determine activity expressed as CR/CRi rate after consolidation therapy. (Phase II)
* To determine feasibility of blood CD34 harvesting after consolidation therapy. (Phase II)
* To determine disease-free and overall survival from CR/CRi. (Phase II)
OUTLINE: This is a multicenter, phase I, dose-escalation study of clofarabine followed by an randomized phase II study. Patients are stratified according to center, and presence of poor prognostic features (WBC at diagnosis ≥ 100,000/μL vs presence of very high risk cytogenetic features -5/5q-, -7/7q-, presence of complex abnormalities \[\> 3 abnormalities\], 3q, t\[6;9\], or t\[9;22\]). Patients are randomized to 1 of 2 treatment arms.
* Induction therapy:
* Arm I: Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
* Arm II: Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
* Consolidation therapy: Patients receive cytarabine IV over 2 hours every 12 hours on days 1-6 and idarubicin IV over 5 minutes once daily on days 4-6.
After completion of study therapy, patients are followed periodically for 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
clofarabine
Given IV
cytarabine
Given IV
idarubicin
Given IV
Arm II
Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
clofarabine
Given IV
cytarabine
Given IV
idarubicin
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clofarabine
Given IV
cytarabine
Given IV
idarubicin
Given IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of 1 of the following by WHO criteria:
* Acute myeloid leukemia (AML) (≥ 20% bone marrow blasts by bone marrow aspiration or biopsy)
* No acute promyelocytic leukemia (M3)
* All cytogenetic groups allowed, except for the following:
* t(15;17)
* t(8;21) or inv(16) AND a WBC count at diagnosis of \< 100,000/μL
* Primary or secondary AML allowed, including AML after myelodysplasia (MDS)
* High-risk MDS (≥ 10% bone marrow blasts by bone marrow aspiration or biopsy)
* No chronic myelogenous leukemia in blast crisis or AML supervening a myeloproliferative disorder
* Previously untreated disease, except for ≤ 14 days of hydroxyurea
* No CNS leukemia
PATIENT CHARACTERISTICS:
* WHO performance status 0-2
* Serum creatinine ≤ 1.0 mg/dL or glomerular filtration rate \> 60 mL/min
* AST/ALT ≤ 2.5 times upper limit of normal (ULN)
* ALP ≤ 2.5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for ≥ 3 months after completion of study treatment
* No active uncontrolled infection
* No HIV positivity
* No psychological, familial, sociological, or geographical conditions precluding compliance with study treatment or follow up
* No concurrent severe uncontrolled cardiovascular disease (i.e., symptomatic congestive heart failure or symptomatic ischemic heart disease \[NYHA class III-IV\])
* No concurrent malignant disease
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No concurrent cytotoxic drugs or experimental therapies (e.g., antiangiogenic drugs, tyrosine kinase inhibitors)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roel Willemze
Role: PRINCIPAL_INVESTIGATOR
EORTC (Phase I) - Leiden University Medical Center, NL
Dominik Selleslag
Role: PRINCIPAL_INVESTIGATOR
EORTC (Phase II) - AZ Sint-Jan, BE
Giovanna Meloni
Role: PRINCIPAL_INVESTIGATOR
GIMEMA (Phase I & II) - Universita Degli Studi "La Sapienza", IT
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A.Z. Sint-Jan
Bruges, , Belgium
Institut Jules Bordet
Brussels, , Belgium
CHU Sart-Tilman
Liège, , Belgium
University Hospital Rebro
Zagreb, , Croatia
Hôpital Saint Antoine AP-HP
Paris, , France
Azienda Ospedallera Universitaria - Policlinico Tor Vergata
Roma, , Italy
Univesita Degli Studi "La Sapienza"
Roma, , Italy
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
Leiden University Medical Center
Leiden, , Netherlands
Radboud University Nijmegen Medical Center
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-06061
Identifier Type: -
Identifier Source: secondary_id
EU-20905
Identifier Type: -
Identifier Source: secondary_id
2006-004912-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GIMEMA-AML-14A
Identifier Type: -
Identifier Source: secondary_id
EORTC-06061
Identifier Type: -
Identifier Source: org_study_id